Amantadine-Induced Cardiac Arrest in a Patient With COVID-19.
| Autor: | Bakhati B; Internal Medicine, Texas Tech University Health Sciences Center Permian Basin, Odessa, USA., Sibi VM; Medicine, North-Western State Medical University named after I.I. Mechnikov, St. Petersburg, RUS., Mekala AP; Internal Medicine, Texas Tech University Health Sciences Center Permian Basin, Odessa, USA., Ronen JA; Internal Medicine, University of California San Francisco Medical Center, San Francisco, USA.; Division of Hospital Medicine, University of California San Francisco School of Medicine, San Francisco, USA., Mungara SS; Internal Medicine, Texas Tech University Health Sciences Center Permian Basin, Odessa, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2022 Jan 17; Vol. 14 (1), pp. e21345. Date of Electronic Publication: 2022 Jan 17 (Print Publication: 2022). |
| DOI: | 10.7759/cureus.21345 |
| Abstrakt: | Amantadine, which is known for its antiviral activity, is presently used as therapy for Parkinson's disease. Adverse effects, such as cardiac arrhythmias, have been described in patients after ingestion of amantadine. Here, we present a patient who suffered a cardiac arrest following ingestion of a low dose of amantadine. A 71-year-old man was admitted to the emergency department for a witnessed cardiac arrest. He had developed an upper respiratory tract infection the preceding week and was prescribed 100 mg of amantadine. Within half an hour of taking the first dose, the patient collapsed. He was found to be in asystole by emergency medical services, and advanced cardiac life support protocols were initiated, including cardiopulmonary resuscitation and intubation for airway protection. However, he sustained multiple recurrences of cardiac arrest, and despite all resuscitation efforts, the patient expired. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2022, Bakhati et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|